Sir Jeremy Farrar. Genius. Archives - Page 2 of 2

eCAM Biomed Global Impact Fund

Search for:

April 2020

Sir Jeremy Farrar, Director of the Wellcome Trust and a UK government adviser – Amanpour – CNN [video]

eCAM2020-07-09T05:19:24+00:00April 7th, 2020|

Christiane speaks with Sir Jeremy Farrar, director of the Wellcome Trust and a UK government adviser, about the race to find coronavirus treatments and a vaccine.

January 2020

PRESS RELEASE. Sharing research data and findings relevant to the novel coronavirus (COVID-19) outbreak

eCAM2020-07-09T05:23:05+00:00January 30th, 2020|

Press release | 31 January 2020 | Sharing research data and findings relevant to the novel coronavirus (COVID-19) outbreak Source: Wellcome Trust The outbreak of the novel coronavirus (COVID-19) represents a [...]

January 2017

PRESS RELEASE. CEPI officially launched 18 Jan 2017

sibiu1182020-07-09T05:22:45+00:00January 18th, 2017|

Global partnership launched to prevent epidemics with new vaccines Media release, Davos 18 Jan 2017 – Coalition for Epidemic Preparedness Innovations A global coalition to create new vaccines for emerging infectious diseases, [...]

Previous 12

Search for:

Follow

COVID-19 Resource Links

• COVID-19 Trusted News

• COVID-19 Resource Links

Think.

People.
Planet.
Principle.
Prosperity.
Trending together.

Think.

MY ECAM Impact Investment Checklist:

1. Think. Is it good for People?
2. Think. Is it good for Planet?
3. Think. Is it meaningful in Principle?

Think.

In the new paradigm of impact investment, in our post-pandemic future, if your answers are “yes, yes, yes” then the chances of your investment to lead to Prosperity and Profitability are probably good.

Think.

Prudent, timely and meaningful impact investment can certainly be a good thing.

Invest in our common future. Private equity for people, planet, principle, prosperity.

twitter

This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Cookie settings ACCEPT

Privacy & Cookies Policy

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these cookies, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may have an effect on your browsing experience.

Necessary Always Enabled

Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.

Non-necessary

Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.

Disclaimer & Agreement

THIS WEBSITE IS:

NOT AN OFFER TO INVEST. NOT A RECOMMENDATION. NOT AN ENDORSEMENT.

FOR EDUCATIONAL AND INFORMATIONAL PURPOSES ONLY.

Under no circumstances should any information presented on this website be construed as an offer to sell, or solicitation of any offer to purchase, any securities or other investments. This website does not contain the information that an investor should consider or evaluate to make a potential investment.

Offering materials relating to potential investments in entities are not available to the general public.

To view this content, you must agree to the following simple and basic terms, in addition to and supplementing the Terms of Use and Privacy Policy:

I confirm and agree that:

I am entering this website only to obtain general information and not for any other purpose.
I understand that this website does not contain the information I would need to consider for an investment, and that such information is only available to a limited group of persons and institutions meeting specified criteria.
I understand that this website has not been reviewed or approved by, filed with, or otherwise furnished to any governmental or similar authority, and is intended only to provide limited information to members of the public who have a legitimate interest in that information for reasons unrelated to making investments.
I understand that this website may make third party information available, will not have verified statements made by the third party, and the presentation of information may omit important information.
I understand that the COVID-19 Pandemic Report by eCAM and The ECAM Post is for educational purposes and social benefit, not for profit.

By registering my information below and clicking “Agree,” I certify that I have read, understand and agree to the foregoing Disclaimer, Terms of Use and Privacy Policy.

AGREE

Peter A. Jensen

President & CEO

About

Innovator. Leader. Collaborator. Entrepreneur. Biologist. Inventor. Producer. Mr. Jensen is a high-performance CEO and business manager with extensive expertise in life sciences, computer sciences, mobile, multimedia, entertainment, fintech, finance and distributed ledger technology. Mr. Jensen earned a Master of Fine Arts (MFA) at UCLA Motion Picture Film and Television Producer’s Program (1988) and a Bachelor of Arts (BA) in Biological Sciences at UCSB (1980) magna cum laude. Mr. Jensen is an experienced key executive business manager and entrepreneur with a superlative track record. Mr. Jensen is focused on delivery of social enterprise ventures with competitive financial returns and extraordinary social impact.

Innovative achievements include:

• First ever Apple Macintosh multimedia system integrator in Los Angeles (1988-93)
• First ever virtual 3D robotic surgery training simulator, tissue realistic, for vascular surgeons (1998)
• First ever Norwegian 2D animated feature film, digital ink&paint&composite&film record, co-produced (1998)
• First ever mobile app, BBC News content, for Ericsson’s first ever smartphone, on Symbian OS. (1999)
• Delivered +50x ROI for early stage venture investors, including the State of Norway, SND. (2000)
• First ever Norwegian 3D animated TV Series for NRK, co-produced (2000)
• First ever Norwegian 3D animated Feature Film, co-produced (2006)
• First ever Distributed Ledger Technology (DLT) Proof-of-Value delivery for EU Tier-1 Bank (2015)
• First ever Vaccine bond to fund-and-find a cure and a vaccine for HIV faster, not-for-profit (2016)
• ORION. The Outbreak Response International Open Network, for pro bono global impact (2019)
• ECAM. The first ever Biomedical Global Impact Private Equity Fund, based in Guernsey and UK (2019)